KPTI
NASDAQ · Biotechnology
Karyopharm Therapeutics Inc
$0.05
-0.01 (-8.65%)
Financial Highlights (FY 2026)
Revenue
220.75M
Net Income
-296,266,835
Gross Margin
95.9%
Profit Margin
-134.2%
Rev Growth
-2.4%
D/E Ratio
3.78
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 95.9% | 95.9% | 58.0% | 58.0% |
| Operating Margin | -104.8% | -94.3% | -17.3% | -17.8% |
| Profit Margin | -134.2% | -127.5% | -18.4% | -20.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 220.75M | 226.17M | 24.30M | 18.75M |
| Gross Profit | 211.76M | 216.97M | 14.09M | 10.87M |
| Operating Income | -231,342,103 | -213,327,758 | -4,201,641 | -3,331,957 |
| Net Income | -296,266,835 | -273,196,876 | -4,467,152 | -3,864,497 |
| Gross Margin | 95.9% | 95.9% | 58.0% | 58.0% |
| Operating Margin | -104.8% | -94.3% | -17.3% | -17.8% |
| Profit Margin | -134.2% | -127.5% | -18.4% | -20.6% |
| Rev Growth | -2.4% | -2.4% | +18.6% | +24.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 358.8K | 358.8K | 49.27M | 39.84M |
| Total Equity | 94.9K | 94.9K | 65.47M | 76.64M |
| D/E Ratio | 3.78 | 3.78 | 0.75 | 0.52 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -230,884,766 | -224,734,147 | -5,147,496 | -4,398,523 |
| Free Cash Flow | — | — | -3,231,735 | -3,403,763 |